OncoSil™ is a single-use brachytherapy device designed for patients with locally advanced unresectable pancreatic cancer (LAPC). It delivers a targeted dose of beta radiation directly into cancerous tissue, working alongside traditional chemotherapy. This approach aims to reduce tumour size, potentially making patients eligible for surgical removal.
Brachytherapy, also known as internal radiation therapy, distinguishes itself by placing a sealed radiation source directly into or adjacent to the cancerous tumour. OncoSil™ stands out in its ability to target tumours with unparalleled precision compared to external beam radiotherapy. By delivering higher doses of radiation while minimising exposure to surrounding healthy tissue, OncoSil™ represents a significant advancement in cancer treatment.
Patient Eligibility and Aim of Treatment
OncoSil™ is specifically designed for patients with locally advanced unresectable pancreatic cancer. In cases where the tumour is too large or too close to nearby blood vessels for safe surgical removal, OncoSil™ offers a ray of hope. The primary goal of OncoSil™ treatment is to shrink the tumour by destroying cancerous tissue. Successful treatment may render some patients eligible for subsequent surgical removal, enhancing the overall effectiveness of the therapeutic approach.
Implantation Procedure
The OncoSil™ implantation procedure involves utilising endoscopic ultrasound, a standard technique performed by trained medical professionals. During this procedure, a flexible, fiber optic tube is passed through the mouth, down the oesophagus, providing a close-up view of the pancreas. The OncoSil™ device is then implanted directly into the tumour via a fine needle. This minimally invasive procedure typically takes between 30 and 60 minutes, with patients being observed for a minimum of four hours post-implantation. Depending on the treating doctor’s assessment, patients may be discharged the same day or require an overnight stay
Aftercare and Side Effects
The healthcare team ensures comprehensive aftercare support, guiding patients through their recovery journey. As with any medical treatment, OncoSil™, coupled with the implantation procedure and associated chemotherapy, may have side effects and associated risks. Treating doctors provide detailed information to patients, allowing them to make informed decisions about their treatment journey.
Company Overview
OncoSil™ is at the forefront of innovation in cancer care, offering a transformative solution for LAPC patients. The company’s commitment to advancing cancer treatment is underscored by its unique brachytherapy system, which has the potential to reshape the standard of care for pancreatic cancer.
OncoSil Limited, traded on the Australian Securities Exchange (ASX: OSL), stands out with its pioneering OncoSil™ brachytherapy system for locally advanced unresectable pancreatic cancer. Investors are drawn to the company’s innovative technology, and current market conditions may present a favourable buying opportunity. Additionally, OncoSil Limited’s recent entry into the European market signifies a significant stride in expanding its global impact, offering new prospects for collaboration and growth. As the company continues to redefine cancer treatment standards, it remains a promising force in the healthcare sector, providing both investors and patients with an optimistic outlook for the future.
OncoSil™ represents a groundbreaking development in cancer treatment, particularly for patients with locally advanced unresectable pancreatic cancer. The precision of its brachytherapy system, coupled with a commitment to patient well-being and aftercare, positions OncoSil™ as a promising solution in the fight against pancreatic cancer. With its listing on ASX: OSL, OncoSil Limited signals not only a commitment to medical innovation but also a promising future in the rapidly evolving field.
